Based on the described background and the PSMA expression demonstrated by several studies, prospective multicentre studies are needed to assess if this therapy might become an affordable option for metastatic TN BC patients with progressive disease after standard-of-care treatments. The gene discussed is FOLH1; the disease is breast cancer.